Volume 97, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



In Sub-Saharan Africa, the prevalence of HIV-associated kidney diseases is as high as 53.3%. Combined antiretroviral treatment (cART), especially tenofovir disoproxil fumarate (TDF), is known to be nephrotoxic. We undertook this cross-sectional study conducted in 2015 at the Regional Hospital Limbe in the Southwest Region of Cameroon to determine the prevalence of renal dysfunction and its correlates among treatment-experienced HIV-infected patients on TDF and treatment-naïve patients. In April 2016, a follow-up was performed on those who had been treatment-naïve and were started on cART after enrolment in the study. We compared 119 patients on TDF-containing regimens with 47 treatment-naïve patients. Proteinuria was significantly more prevalent, and creatinine was significantly higher among treatment-naïve patients than among those on treatment (52.2% versus 26.1%; = 0.003 and = 0.009, respectively). The proportion of patients with an estimated glomerular filtration rate (eGFR) < 60 mL/minute was significantly higher among treatment-naïve patients than among those on TDF treatment (40.4% versus 24.4%; = 0.041). Treatment-naïve patients displayed an improvement in creatinine levels and eGFR after 6 months of treatment. To the best of our knowledge, this is the first study to investigate the impact of TDF on renal parameters in Cameroon. TDF appears to be safe and does not appear to be a significant cause of renal impairment. However, renal parameters should be monitored regularly, as recommended by the guidelines.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Chadwick DR, Sarfo FS, Kirk ES, Owusu D, Bedu-Addo G, Parris V, Owusu AL, Phillips R, , 2015. Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol 16: 195.[Crossref] [Google Scholar]
  2. Okafor UH, Unuigbe EI, Chukwuonye E, , 2016. Prevalence and clinical and laboratory characteristics of kidney disease in anti-retroviral-naive human immunodeficiency virus-infected patients in south-south Nigeria. Saudi J Kidney Dis Transpl 27: 129134.[Crossref] [Google Scholar]
  3. Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, Patel U, , 2014. The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health 2: e174e181.[Crossref] [Google Scholar]
  4. FolefackKaze F, Kengne AP, PefuraYone EW, NdamFemben NS, Ashuntantang G, , 2013. Renal function, urinalysis abnormalities and correlates among HIV-infected Cameroonians naive to antiretroviral therapy. Saudi J Kidney Dis Transpl 24: 12911297.[Crossref] [Google Scholar]
  5. Mallipattu SK, Salem F, Wyatt CM, , 2014. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int 86: 259265.[Crossref] [Google Scholar]
  6. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, , 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191201.[Crossref] [Google Scholar]
  7. Pozniak AL, 2006. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes–a 96-week analysis. J Acquir Immune Defic Syndr 43: 535540. [Google Scholar]
  8. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK, , 2002. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16: 12571263.[Crossref] [Google Scholar]
  9. Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, Maotoe T, Fox M, , 2011. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 25: 16031609.[Crossref] [Google Scholar]
  10. De Beaudrap P, 2010. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses 26: 12211227.[Crossref] [Google Scholar]
  11. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD, , 2010. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 16671678.[Crossref] [Google Scholar]
  12. Solomon MM, 2014. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 28: 851859.[Crossref] [Google Scholar]
  13. Young B, Buchacz K, Baker RK, Moorman AC, Wood KC, Chmiel J, Brooks JT, , 2007. Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic) 6: 178187.[Crossref] [Google Scholar]
  14. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C, Jr Klein D, , 2010. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 53: 6269.[Crossref] [Google Scholar]
  15. Labarga P, 2009. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23: 689696.[Crossref] [Google Scholar]
  16. Gupta SK, , 2009. Can the SMART study data be used to assess risk factors for renal disease? Ann Intern Med 150: 282, author reply 282–283.[Crossref] [Google Scholar]
  17. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA, , 2009. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 10: 329336.[Crossref] [Google Scholar]
  18. Fux CA, 2007. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12: 11651173. [Google Scholar]
  19. Agbaji OO, Agaba PA, Idoko JA, Taiwo B, Murphy R, Kanki P, Ekong E, , 2011. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians. West Afr J Med 30: 164168. [Google Scholar]
  20. Gupta SK, 2005. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40: 15591585.[Crossref] [Google Scholar]
  21. Kengne AP, Kaze FF, Dzudie A, Awah PK, Ngu KB, , 2007. HIV/AIDS occurrence in the main university teaching hospital in Cameroon: audit of the 2001 activities of the service of internal medicine. J Int Assoc Physicians AIDS Care (Chic) 6: 6165.[Crossref] [Google Scholar]
  22. Emem CP, Arogundade F, Sanusi A, Adelusola K, Wokoma F, Akinsola A, , 2008. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant 23: 741746.[Crossref] [Google Scholar]
  23. Fabian J, Naicker S, Venter WD, Baker L, Naidoo S, Paget G, Wadee S, , 2009. Urinary screening abnormalities in antiretroviral-naive HIV-infected outpatients and implications for management—a single-center study in South Africa. Ethn Dis 19 (1 Suppl 1): S1-80-5. [Google Scholar]
  24. Wools-Kaloustian K, Gupta SK, Muloma E, Owino-Ong’or W, Sidle J, Aubrey RW, Shen J, Kipruto K, Zwickl BE, Goldman M, , 2007. Renal disease in an antiretroviral-naive HIV-infected outpatient population in western Kenya. Nephrol Dial Transplant 22: 22082212.[Crossref] [Google Scholar]
  25. Obirikorang C, Osakunor DN, Ntaadu B, Adarkwa OK, , 2014. Renal function in Ghanaian HIV-infected patients on highly active antiretroviral therapy: a case-control study. PLoS One 9: e99469.[Crossref] [Google Scholar]
  26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1150.[Crossref] [Google Scholar]
  27. Garko SS, Ibinaiye PO, Abba SM, Ahmed A, Tanimu SS, Okere PC, , 2015. The utilization of diagnostic ultrasound in the evaluation of the kidneys in HIV-associated nephropathy. West Afr J Radiol 22: 2026.[Crossref] [Google Scholar]
  28. Han TM, Naicker S, Ramdial PK, Assounga AG, , 2006. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 69: 22432250.[Crossref] [Google Scholar]
  29. Wyatt CM, Shi Q, Novak JE, Hoover DR, Szczech L, Mugabo JS, Binagwaho A, Cohen M, Mutimura E, Anastos K, , 2011. Prevalence of kidney disease in HIV-infected and uninfected Rwandan women. PLoS One 6: e18352.[Crossref] [Google Scholar]
  30. Msango L, Downs JA, Kalluvya SE, Kidenya BR, Kabangila R, Johnson WD, Jr Fitzgerald DW, Peck RN, , 2011. Renal dysfunction among HIV-infected patients starting antiretroviral therapy. AIDS 25: 14211425.[Crossref] [Google Scholar]
  31. Peters PJ, Moore DM, Mermin J, Brooks JT, Downing R, Were W, Kigozi A, Buchacz K, Weidle PJ, , 2008. Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 74: 925929.[Crossref] [Google Scholar]
  32. Reid A, 2008. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 46: 12711281.[Crossref] [Google Scholar]
  33. Ayokunle DS, Olusegun OT, Ademola A, Adindu C, Olaitan RM, Oladimeji AA, , 2015. Prevalence of chronic kidney disease in newly diagnosed patients with human immunodeficiency virus in Ilorin, Nigeria. J Bras Nefrol 37: 177184.[Crossref] [Google Scholar]
  34. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD, , 2004. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18: 541546.[Crossref] [Google Scholar]
  35. Atta MG, , 2010. Diagnosis and natural history of HIV-associated nephropathy. Adv Chronic Kidney Dis 17: 5258.[Crossref] [Google Scholar]
  36. Owiredu WK, Quaye L, Amidu N, Addai-Mensah O, , 2013. Renal insufficiency in Ghanaian HIV infected patients: need for dose adjustment. Afr Health Sci 13: 101111. [Google Scholar]
  37. Ross MJ, , 2014. Advances in the pathogenesis of HIV-associated kidney diseases. Kidney Int 86: 266274.[Crossref] [Google Scholar]
  38. Medapalli RK, 2012. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr 60: 393399.[Crossref] [Google Scholar]
  39. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O’Hare AM, , 2007. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 18: 29682974.[Crossref] [Google Scholar]
  40. Kengne AP, Awah PK, Fezeu L, Mbanya JC, , 2007. The burden of high blood pressure and related risk factors in urban sub-Saharan Africa: evidences from Douala in Cameroon. Afr Health Sci 7: 3844. [Google Scholar]
  41. Kinai E, Hanabusa H, , 2005. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 19: 20312033.[Crossref] [Google Scholar]
  42. Diana NE, Naicker S, , 2016. Update on current management of chronic kidney disease in patients with HIV infection. Int J Nephrol Renovasc Dis 9: 223234.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 25 Jan 2017
  • Accepted : 06 Jul 2017
  • Published online : 28 Aug 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error